Fate Therapeutics, Inc.
Income Statement
| Line Item | FY2017 | FY2016 | FY2015 | FY2013 | FY2012 | FY2011 |
|---|---|---|---|---|---|---|
| Revenue | $4.1M | $4.4M | $2.4M | $971.0K | $2.7M | $1.2M |
| Cost of Revenue | — | — | — | — | — | — |
| Gross Profit | — | — | — | — | — | — |
| Gross Margin | — | — | — | — | — | — |
| Operating Expenses | ||||||
| Research & Development | $34.4M | $26.5M | $19.9M | $12.0M | $12.0M | $9.9M |
| SG&A Expense | $11.9M | $9.9M | $10.4M | $6.6M | $4.2M | $4.6M |
| Operating Income | $-42.1M | $-32.0M | $-27.8M | $-17.7M | $-13.6M | $-13.3M |
| Operating Margin | -1,025.9% | -726.1% | -1,142.8% | -1,820.3% | -507.8% | -1,136.2% |
| Interest Expense | $1.3M | $1.6M | $2.2M | $796.0K | $487.0K | $127.0K |
| Pretax Income | — | — | — | — | — | — |
| Income Tax Expense | — | — | — | — | — | — |
| Net Income | $-43.0M | $-33.5M | $-30.0M | $-20.9M | $-14.2M | $-13.4M |
| Net Margin | -1,046.1% | -760.2% | -1,233.7% | -2,151.8% | -533.3% | -1,147.6% |
| EPS (Basic) | $-1.02 | $-1.05 | $-1.18 | $-3.54 | $-13.06 | $-16.16 |
| EPS (Diluted) | $-1.02 | $-1.05 | $-1.18 | $-3.54 | $-13.06 | $-16.16 |
| Shares Outstanding (Basic) | 52.6M | 41.4M | 28.7M | 20.4M | 1.3M | — |
| Shares Outstanding (Diluted) | 52.6M | 41.4M | 28.7M | 20.4M | 1.3M | — |
| Dividends Per Share | — | — | — | — | — | — |